4-Bromo-2-oxo-1-[[4-(trifluoromethoxy)phenyl]methyl]pyridine-3-carbonitrile | 950201-48-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-Bromo-2-oxo-1-[[4-(trifluoromethoxy)phenyl]methyl]pyridine-3-carbonitrile
• CAS: 950201-48-6
• 化学式: C₁₄H₈BrF₃N₂O₂
• 分子量: 373.129
• InChiKey: UNGTUGVXKWRDPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  53.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(2-吗啉乙氧基)苯基硼酸频哪醇酯 、 4-Bromo-2-oxo-1-[[4-(trifluoromethoxy)phenyl]methyl]pyridine-3-carbonitrile 在 四(三苯基膦)钯 sodium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.17h， 以65%的产率得到4-[4-(2-Morpholin-4-ylethoxy)phenyl]-2-oxo-1-[[4-(trifluoromethoxy)phenyl]methyl]pyridine-3-carbonitrile
  参考文献：
  名称：

  WO2007/104783

  摘要：

  公开号：
• 作为产物：
  描述：

  4-三氟甲氧基溴苄 在 sodium hydroxide 、 水 、 potassium carbonate 、 三溴氧磷 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 21.0h， 生成 4-Bromo-2-oxo-1-[[4-(trifluoromethoxy)phenyl]methyl]pyridine-3-carbonitrile
  参考文献：
  名称：

  WO2007/104783

  摘要：

  公开号：

文献信息

• 1,4 disubstituted 3 cyano pyridone derivatives and their use as positive allosteric modulators of mGluR2 receptors
  申请人：Ortho-McNeil-Janssen Pharmaceuticals, Inc.

  公开号：EP2426125A1

  公开（公告）日：2012-03-07

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是符合式 (I) 的新型吡啶酮衍生物 其中所有基团在申请和权利要求中均有定义。根据本发明的化合物是代谢受体-亚型 2（"mGluR2"）的正异位调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及涉及代谢受体的 mGluR2 亚型的疾病。特别是，这类疾病是选自焦虑症、精神分裂症、偏头痛、抑郁症和癫痫组的中枢神经系统疾病。本发明还涉及药物组合物和制备此类化合物及组合物的工艺，以及使用此类化合物预防和治疗涉及 mGluR2 的此类疾病。
• 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS
  申请人：Imogai Hassan Julien

  公开号：US20100166655A1

  公开（公告）日：2010-07-01

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
• 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors
  申请人：JANSSEN PHARMACEUTICALS, INC.

  公开号：US20140315903A1

  公开（公告）日：2014-10-23

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
• US8841323B2
  申请人：——

  公开号：US8841323B2

  公开（公告）日：2014-09-23
• US9266834B2
  申请人：——

  公开号：US9266834B2

  公开（公告）日：2016-02-23